It's time to emphasise the economics in health economics. Victoria Jordan discusses the health economics of the UK-US Economic Prosperity Deal and plans increase NICE's baseline threshold use, the first change since its introduction in the early 2000s. abpi.uksouth01.umbraco.io/media/blogs/...

Alzheimer’s devastates the lives of patients and their families, costing billions in care. New treatments that can slow the disease’s progression in its early stages have recently been licensed in the UK - yet NHS patients are still being denied access. Find out more: www.ourcommongoal.org.uk

#ABSWawards As we prepare for the ABSW Awards 2026, we want to thank the partners whose continued support helps us celebrate excellence in science journalism... @abpi.bsky.social Dr Katharine Giles Fund @royalsociety.org AlphaGalileo Want to be an ABSW Awards partner? Find how👉 zurl.co/gPGgo

Publication of 'A Common Understanding 2025' marked an important milestone for collaborative working in Scotland earlier this year. It shows how partnership across industry, academia & the NHS can improve patient care & drive innovation. www.gov.scot/publications...

We’re proud to share our guidance on creating successful NHS-industry partnerships in Northern Ireland’s health & social care system. Developed with @niconfederation.bsky.social, it’s designed to accelerate innovation and improve patient outcomes. www.abpi.org.uk/publications...

Earlier this year we launched joint guidance with @welshnhsconfed.bsky.social to help the NHS and industry work together more confidently, transparently & effectively. 📘 Download here to create successful partnerships for your organisation www.nhsconfed.org/publications... #PartnershipWorking

NHS–industry partnership guidance is now in place across all 4 UK nations. Developed with @nhsconfed.org, @welshnhsconfed.bsky.social, @niconfederation.bsky.social, and the Scottish Government, these frameworks support better outcomes for patients ⬇️ Find out more at www.abpi.org.uk/partnerships/

The VPAG payment rate for newer medicines will be 14.5% in 2026. With the addition of the 1% investment programme, the total rebate for newer medicines in 2026 will be 15.5% of revenues. www.abpi.org.uk/media/news/2...

There’s been a drop in ppl participating in interventional industry clinical trials 📉 There are many potential reasons for this - lots of action underway to fix it 🔧 We're proposing further measures in our latest report. abpi.org.uk/publications... @nihr.bsky.social

Did you know the 150-day target for setting up industry clinical trials has 3 parts? ⏱️🧪 We’re on track with some — but others need work. Read our latest report: www.abpi.org.uk/publications... @nihr.bsky.social

🚨 Today's US–UK trade agreement "...is an important step towards ensuring patients can access the innovative medicines needed to improve wider NHS health outcomes.” Read the full response from our Chief Executive @torbett.bsky.social abpi.org.uk/media/news/2...

Acid Sphingomyelinase Deficiency (ASMD) is a rare disease that shortens the lives of children & adults. Treatments can halt symptoms & reverse disease progression, but many UK patients cannot access these medicines, even though they are available in over 50 countries. www.ourcommongoal.org.uk

Sepsis is the body's reaction to a serious infection and is responsible thousands of deaths a year. Antibiotics are essential for treating #sepsis but rising resistance means we must find new ones. Learn more: www.togetherforantibiotics.org.uk #TogetherForAntibiotics #WAAW #WAAW2025

Treating pneumonia without antibiotics is like a hot-air balloon without gas. This week is World Antimicrobial Awareness Week and we’re highlighting how #AntimicrobialResistance remains a threat to modern medicine as we know it. www.togetherforantibiotics.org.uk #TogetherForAntibiotics #WAAW2025

NHS patients with blood cancer can only access half the approved medicines for their condition despite many of these treatments being available in other countries The question: will the UK continue to leave blood cancer patients behind or give them access to new treatments? www.ourcommongoal.org.uk

Scotland's Life Sciences Strategy is out today, setting out a vision of how to boost the sector to benefit Scottish patients and the economy. @scottishgovernment.bsky.social Read our response: www.abpi.org.uk/media/news/2...

Treatments for kidney disease are under threat from antibiotic resistance. Without antibiotics, procedures like dialysis become far riskier. Find out more: www.togetherforantibiotics.org.uk #TogetherForAntibiotics #WAAW #WAAW2025 #AMR

ABPI Wales Head of External Affairs Joe Castle was joined by the Welsh First Minister @ the Senedd to discuss joint @welshnhsconfed.bsky.social guidance covering how industry & the NHS can work together to improve patient outcomes & support innovation across Wales. www.nhsconfed.org/publications...

What if our treatments no longer worked? Antibiotics are one of the most powerful tools in healthcare. But resistance to them is rising. Learn more: togetherforantibiotics.org.uk #WAAW #WAAW2025 #AMR

New breast cancer treatments can extend patients’ lives, yet some remain unavailable in parts of the UK, even though people in the US and many European countries can access them. Will the UK invest in cutting-edge therapies, or deny them to patients? www.ourcommongoal.org.uk/breast-cancer/

ENG: www.nhsconfed.org/news/new-gui... CYM: www.nhsconfed.org/news/canllaw...

📣 New guidance launch 📣 Ahead of #WelshConfed25, we have renewed our partnership with @abpi.bsky.social to launch a joint guidance that offers practical tools to help NHS and pharmaceutical organisations develop, implement and evaluate partnerships to improve patient outcomes. Links 👇

Out today: Our new joint guidance with @welshnhsconfed.bsky.social to help create more effective, transparent and transformative partnerships between the NHS and the pharmaceutical industry across Wales. Guidance available now ahead of #WelshConfed25 www.nhsconfed.org/publications...

Today @nihr.bsky.social has announced 14 new Primary Care Commercial Research Delivery Centres 🎉 Our colleague Dr Janet Valentine has welcomed these as "a means of offering more patients the opportunity to access the latest treatments in development." Read more: www.nihr.ac.uk/news/14-new-...

We’re celebrating #BiologyWeek! 🎉 A biology background can lead to many careers in the pharmaceutical industry. Remi Goldsmith helps shape policies that help researchers turn scientific ideas into future treatments. www.abpi.org.uk/careers/job-... #iamabiologist @rsb.org.uk

Caleb Meath helps to develop policies that allow researchers in the pharmaceutical industry to use health data to improve patient care. Find out more about careers in the pharmaceutical industry: www.abpi.org.uk/careers/job-... #IAmABiologist #BiologyWeek

This week is the Royal Society of Biology's #BiologyWeek which highlights the value of a bioscience degrees, what they can lead to. There is a wide range of career paths available in the pharmaceutical industry - find out more about careers: www.abpi.org.uk/careers/job-... #iamabiologist

Published for #NICON25 - guidance from us and @niconfederation.bsky.social on creating successful NHS-industry partnerships. Together we will harness the power of partnership to improve care and deliver lasting value for people, systems, and society. #PowerofPartnerships bit.ly/4nV2Mp4

We're very pleased to be supporting the #NICON25 conference - now underway! @niconfederation.bsky.social By harnessing the strength of the health service, the life sciences sector, and Northern Ireland’s academic prowess, we can deliver for patients.

Joanna Jenkinson leads on research and development policy at the ABPI, from discovery science & pre-clinical all the way through to clinical research and development, including emerging technologies and innovative R&D design. www.abpi.org.uk/careers/job-... #iamabiologist @rsb.org.uk #BiologyWeek

This week we are celebrating #BiologyWeek, highlighting the varied career paths Biology background can lead you to within the pharmaceutical industry. Find out more about careers in the pharmaceutical industry: lnkd.in/gQGgd5KM #iamabiologist @rsb.org.uk

Topics from the use of health data for research to the medicines supply chain are explained in a new set of videos from @abpi.bsky.social. The series of short clips cover key topics central to the ABPI work and mission. Head to their YouTube page to see the full list here: lnkd.in/ecCH_hPN

#CPC25 discussions about industrial strategy. Lord Willet's Chair of the Resolution Foundation and Chair of the Regulatory Innovation Office has recognised how important regulation is to growth and investors. Read our report on Regulation: www.abpi.org.uk/publications...

Great session with @astra-zeneca.bsky.social UK today at #CPC25 on the potential of life sciences. For Shadow Health Minister Dr Caroline Johnson, important recognition that we need to get new medicines to patients quicker.

📦 From research labs to your pharmacy… 🛣️ Our supply chain video explains how medicines make their journey through the supply chain to reach patients. Watch the full video⬇️ www.abpi.org.uk/value-and-ac...

🚨NEW: @nhsconfed.org has published a new resource hub on vaccination, to help the NHS make sure that everyone who could benefit from vaccination takes it up. We were happy to help support the publication. www.nhsconfed.org/vaccination-... #VaccinesSaveLives

🚨New resource on the ABPI website: Check out our library of industry-charity partnership case studies. Partnerships help improve outcomes for patients, address healthcare challenges, and drive innovation. Visit our library: bit.ly/3IFQtO3 @pifonline.bsky.social

For Health Minister @ashleydaltonmp.bsky.social, vaccination sits across all three shifts in the #NHS10YearPlan. "We need to be in communities, that's why the neighbourhood health service will be so important." #LabourConference2025 @ippr.org @age-uk.bsky.social

At #Lab25, our President Russell Abberley is discussing the future of UK vaccination policy with @ashleydaltonmp.bsky.social, Darius Hughes of Moderna, Caroline Abrahams of @age-uk.bsky.social & Sebastian Rees of @ippr.org

At #Lab25 we have been discussing innovation, life sciences & the #NHS10YearPlan, hosted by @labourtogether.bsky.social @steveyemm-mp.bsky.social highlighted challenges being faced by industry, and said it is vital that government addresses those to deliver for patients.

In the lead up to the next Senedd election, we are calling on Members of the Senedd to champion and support long-term investment in clinical research, embedding research in the NHS, as business as usual. Read our latest blog: www.abpi.org.uk/media/blogs/...

ICYMI: @torbett.bsky.social spoke to BBC Business earlier about investment in medicines. The UK spends just 9% of the NHS budget on medicines. For most of Europe it's 14% - 20%. This gap leaves the UK at risk of missing out on investment. We believe it is possible to find a solution. 👇

🧵The UK is fortunate to have an excellent science base which continues to offer world-class scientific expertise and globally respected academic institutions. It is also one of the world’s most vibrant environments for biotech and spinout companies. (1/2)

🚨Out today: our manifesto to unlock Scotland’s full potential in life sciences & innovation. 🧬 @torbett.bsky.social: With the right policy choices, Scotland can become a powerhouse for discovery, development & delivery of medicines, vaccines & diagnostics. More: bit.ly/4gnzFHS

This is an important publication that outlines the current status of NAMs, as well as the challenges and opportunities associated with their adoption. We were pleased to feed into this report, alongside @nc3rs.bsky.social and @mhragovuk.bsky.social. Read more below. ⬇️

ICYMI: Our Chief Exec @torbett.bsky.social was on the Today programme this morning, discussing the sad news that life sciences investment is being withdrawn from the UK. Listen again here from about 16 mins and 45 seconds in: www.bbc.co.uk/sounds/play/...

The pharmaceutical industry invests more in R&D than any other sector – driving the discovery of new medicines and vaccines that improve health outcomes for patients and strengthen the UK economy. (1/3)🧵

Today's Guardian explains why a deal with our industry on medicines is needed. "In theory, the current voluntary agreement can run unaltered all the way to 2028, but if that were to happen it would be a disaster for the government’s life sciences strategy." www.theguardian.com/business/nil...

Our Chief Exec @torbett.bsky.social spoke to Times Radio about medicine rebates. The government's offer would still mean the industry paying £13 billion back to government over 3 years - 3 times more than any other European country. We could not accept that, but hope to continue discussions.

The accelerated review of the VPAG scheme has concluded without agreement, but the issues it was set up to resolve continue to demand urgent action. We want to continue constructive dialogue with government to find a solution. Our statement here: www.abpi.org.uk/media/news/2...